Six-Year Regression and Progression of Cervical Lesions of Different Human Papillomavirus Viral Loads in Varied Histological Diagnoses by Wang, Shao-Ming et al.
SIX-YEAR REGRESSION AND PROGRESSION OF CERVICAL
LESIONS OF DIFFERENT HPV VIRAL LOADS IN VARIED
HISTOLOGICAL DIAGNOSES
Shao-Ming WANG, M.D.,
Department of Cancer Epidemiology, Cancer Institute/Hospital, Chinese Academy of Medical
Sciences and Peking Union Medical College, 17 South Panjiayuan Lane, Beijing 100021, China
Danny COLOMBARA, MPH,
1Cancer Institute/Hospital, Chinese Academy of Medical Sciences and Peking Union Medical
College, 17 South Panjiayuan Lane, Beijing 100021, China 2Department of Epidemiology, School
of Public Health, University of Washington, 1959 Northeast Pacific Street, Seattle, Washington
98195, USA
Ju-Fang SHI, M.D., Ph.D.,
Cancer Institute/Hospital, Chinese Academy of Medical Sciences and Peking Union Medical
College, 17 South Panjiayuan Lane, Beijing 100021, China
Fang-Hui ZHAO, M.D., Ph.D.,
Cancer Institute/Hospital, Chinese Academy of Medical Sciences and Peking Union Medical
College, 17 South Panjiayuan Lane, Beijing 100021, China
Jing LI, M.D., Ph.D.,
Cancer Institute/Hospital, Chinese Academy of Medical Sciences and Peking Union Medical
College, 17 South Panjiayuan Lane, Beijing 100021, China
Feng CHEN, B.S.,
Cancer Institute/Hospital, Chinese Academy of Medical Sciences and Peking Union Medical
College, 17 South Panjiayuan Lane, Beijing 100021, China
Wen CHEN, M.D., Ph.D.,
Cancer Institute/Hospital, Chinese Academy of Medical Sciences and Peking Union Medical
College, 17 South Panjiayuan Lane, Beijing 100021, China
Shu-Min LI, M.D.,
Cancer Institute/Hospital, Chinese Academy of Medical Sciences and Peking Union Medical
College, 17 South Panjiayuan Lane, Beijing 100021, China
Xun ZHANG, M.D.,
Cancer Institute/Hospital, Chinese Academy of Medical Sciences and Peking Union Medical
College, 17 South Panjiayuan Lane, Beijing 100021, China
Qin-Jing PAN, M.D.,
Cancer Institute/Hospital, Chinese Academy of Medical Sciences and Peking Union Medical
College, 17 South Panjiayuan Lane, Beijing 100021, China
Jerome L. BELINSON, M.D.,
*Corresponding to You-Lin Qiao, Cancer Institute/Hospital, Chinese Academy of Medical Sciences, 17 South Panjiayuan Lane,
Chaoyang District, Beijing, 100021, China; Phone: +86-10-8778-8489; Fax: +86-10-6771-3648; qiaoy@cicams.ac.cn.
Disclosure Statement
All authors declare that they have no conflicts of interest.
NIH Public Access
Author Manuscript
Int J Gynecol Cancer. Author manuscript; available in PMC 2014 May 01.
Published in final edited form as:













Women’s Health Institute, Cleveland Clinic, 9500 Euclid Avenue Cleveland, Ohio 44195, USA
Jennifer S. SMITH, Ph.D., and
Gillings School of Global Public Health, University of North Carolina, 135 Dauer Drive, Chapel
Hill, North Carolina 27599, USA
You-Lin QIAO, M.D., Ph.D.
Cancer Institute/Hospital, Chinese Academy of Medical Sciences and Peking Union Medical
College, 17 South Panjiayuan Lane, Beijing 100021, China
Abstract
Objective—This study aims to evaluate HPV viral load as a biomarker for triage into colposcopy
and CIN2 therapy, in order to reduce the colposcopy referral rate and CIN2 over treatment in low
resource settings.
Methods—In 1999, 1997 women aged 35–45 in Shanxi, China, received six cervical screenings
with pathological confirmation. In 2005, 1461 histologically normal women, 99 with cervical
intraepithelial neoplasia (CIN) grade 1 (CIN1), and 30 with CIN grade 2 or worse (CIN2+) were
rescreened in a follow-up study. HPV was detected by Hybrid Capture 2. Viral load, estimated by
the ratio of relative light units to standard positive control, was categorized into four groups:
negative (<1.0), low (≥1.0, <10.0), moderate (≥10.0, <100.0) and high (≥100.0). We estimated
cumulative incidence of CIN2+ by viral load subgroups and calculated adjusted hazard ratios
(aHR) for CIN2+ using Cox proportional hazards regression.
Results—Cumulative incidence of CIN2+ increased with baseline HPV viral load among normal
women and women with CIN1 at baseline (P-trend<0.001). Repeat moderate-high viral load was
associated with the highest risk for CIN2+ (aHR=188.8, 95% confidence interval: 41.2–864.1).
Raising the RLU/PC cutoff from 1.0 to 10.0 for colposcopy greatly reduced the referral rate from
18.1% to 12.9%. It also increased the specificity (84.8% vs. 90.4%), the positive predictive value
(22.5% vs. 28.9%), and the positive likelihood ratio (6.4 vs. 8.9), yet with loss of the sensitivity by
12% (97.6% vs. 85.7%). Among women with CIN2 at baseline, 56% regressed to normal, 24%
regressed to CIN1, 4% remained CIN2, and 16% progressed to CIN3+.
Conclusions—Locales using HPV testing as the primary screening method, and lacking high-
quality cytology-based screening, should consider viral load as an alternative to colposcopy triage
for women over age 35. Viral load may also predict CIN2 progression until additional biomarkers
become available.
Keywords
Cervical Intraepithelial Neoplasia (CIN); Hazard Ratios (HR); Human Papillomavirus (HPV) viral
load; Regression; Progression
Introduction
Persistent infection with carcinogenic human papillomavirus (HPV) types is the cause of
virtually all cervical cancer. HPV DNA tests are highly sensitivity (97.5%) for detection of
cervical intraepithelial neoplasia grade 3 or worse (CIN3+). 1 Randomized controlled trials
have demonstrated that HPV testing, followed by cytological triage of HPV-positive
women, is a good choice as a primary screening method in older women. 2 However, high-
quality cytologic screening is unavailable in many locales and highly sensitive primary HPV
screening could lead to excessive colposcopy referral and unnecessary health expenditures.
Therefore, there is a need to develop triage methods for HPV positive women that are
appropriate for low resource settings.
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Under current clinical guidelines recommended by WHO, 3 women with mild cervical
intraepithelial neoplasia (CIN1) are to be monitored while those with CIN grade 2 or worse
(CIN2+) lesions are usually referred for immediate therapy. However, up to 40–68% of
CIN2 may spontaneously regress, 4,5 suggesting overtreatment of some women. Novel
biomarkers are needed for further triage of these women, to reduce the burden of
overtreatment on individual women and the healthcare system as a whole. A previous cross-
sectional study examined HPV viral load as a possible triage candidate.6 However, evidence
from prospective studies is needed to support these findings.
Therefore, our objectives were to evaluate HPV viral load as a biomarker for triage into
colposcopy and CIN2 therapy, in order to reduce the colposcopy referral rate and CIN2 over
treatment in low resource settings. We conducted a population-based cohort study in
Xiangyuan County, Shanxi Province, China — an area with high cervical cancer mortality
(52/100,000).7 The rate of cervical lesion regression and progression, and the risk for
developing precancerous cervical lesions in association with HPV viral load and baseline
histological status, were evaluated at a six-year follow-up assessment.
Materials and Methods
Baseline Study Procedures
In 1999, a cross-sectional comparative trial was carried out to evaluate multiple screening
techniques for the detection of cervical neoplasia. 8,9 1997 non-pregnant women 35–45
years old, with no history of cervical screening or hysterectomy were enrolled in a cohort
through the Women and Children’s Hospital in Xiangyuan County. After providing written
informed consent, participants completed a standardized questionnaire regarding
demographic information and risk factors. Participants also underwent a cervical
examination consisting of cervical screening tests and a minimum of four biopsies. Cervical
screening included vaginal swabs for a HPV-DNA testing, liquid-based cytology, visual
inspection with acetic acid (VIA), and colposcopy. HPV infection was assessed using the
Hybrid Capture 2 (HC2) assay (QIAGEN, Gaithersburg, Maryland). Abnormalities
discovered via colposcopy were biopsied using a multiple quadrant protocol. If no
abnormalities were observed in a given quadrant, a random biopsy was taken from that
quadrant at either 2, 4, 8, or ten o’clock on the exocervix at the squamocolumnar junction
(SCJ), as appropriate. Endocervical curettage (ECC) was also performed on each participant.
Women with histologically confirmed CIN2+ lesions were offered immediate, affordable,
standard therapy on a voluntary basis, specifically, the loop electrosurgical excision
procedure, cone biopsy treatment or hysterectomy, according to local guidelines.
Follow-up Study Procedures
All women with baseline confirmed CIN1 or less and with baseline HPV and cytological
results were invited to participate in a follow-up study in 2005 at the hospital where they
were originally enrolled.9 Women with baseline confirmed CIN2+ were followed up as well,
but only those without therapy during the past 6 years were included into this analysis. After
obtaining written informed consent, we collected self-reported cervical treatment history
since the baseline examination as well as updated sociodemographic and risk factor data.
Women reporting cervical therapy nine months or more after baseline were administered a
questionnaire gathering detailed treatment information including date, hospital, and type of
therapy.
Screening tests included ThinPrep liquid-based cytology (Hologic, Marlborough,
Massachusetts), HC2 HPV testing, VIA and colposcopy. Abnormalities found during
colposcopy were biopsied at the lesion site. ECC was performed if the SCJ was not
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visualized. Cytological results were interpreted using the Bethesda classification system.10
Women were referred for a second colposcopy if they had either atypical squamous cells of
undetermined significance (ASCUS) with HPV-positive results at the follow-up visit, or
other worse cytological abnormalities. Cervical biopsies and treatment followed the same
multiple quadrant protocol and therapy guidelines as at baseline.
Of the 1997 participants in the baseline study, 59 (2.9%) women were ineligible due to
incomplete baseline testing data, 1831 (91.7%) women attended the follow-up study, and an
additional 107 (5.4%) were lost to follow-up. Study personnel traced women lost to follow-
up through home visits. General demographic information, reasons for nonparticipation, and
history of cervical disease and related treatment were collected in brief interviews with the
surviving women. For deceased subjects, the decedent’s close relatives or local doctors were
interviewed for the cause and date of death and other important sociodemographic
characteristics. Death certificates were not routinely completed in this area.
Institutional review board approval was obtained from the Cancer Institute/Hospital,
Chinese Academy of Medical Sciences, the Cleveland Clinic, and the University of North
Carolina.
Quality assurance procedures
Personnel were trained before the start of studies. Specimens were shipped to Cancer
Institute, Chinese Academy of Medical Sciences (CICAMS) for blinded testing. Within two
weeks after sampling, senior technicians at CICAMS assessed HPV viral load using the
HC2 assay. Cervical biopsy slides were prepared and read by senior pathologists at
CICAMS. Women reporting a history of treatment for suspicion of CIN or cancer during the
past six years had their treatment records reviewed and the corresponding slides reread by
CICAMS pathologists for further confirmation.9 Pathology was the gold standard endpoint
measure, final classification was based on a combination of testing measures for women
lacking pathological results.1
Statistical analysis
HPV viral load was measured using the ratio of relative light units to standard positive
control (RLU/PC) as a surrogate. HPV viral load is typically divided into positive (≥1.0) and
negative (<1) groups. Based on previous publications and the trisection cutoff of our
positive viral load data in this study,6 we divided the positive group into three viral load
subgroups for our analysis: low (≥1.0, <10.0), moderate (≥10.0, <100.0) and high (≥100.0).
Socio-demographic characteristics of participants were described by frequencies and
proportions, stratified by baseline HPV viral load. One-way ANOVA and Pearson’s chi-
square tests were used to compare continuous and categorical factors by viral load
categories, respectively. Sensitivity, specificity, predictive values and likelihood ratios were
calculated and compared among women with different HPV viral loads.
For women with CIN1 or normal histological status at baseline, we calculated the
cumulative incidence of CIN2+. Using Cox proportional hazards regression, the adjusted
Hazard Ratios (aHR) of CIN2+ and 95% confidence intervals (CI) were analyzed according
to different combinations of HPV viral load at baseline and follow-up, adjusted for age,
number of lifetime full-term births, and number of lifetime sexual partners. The association
between categories of HPV viral load and the incidence of CIN2+ lesions among women
with CIN1 or less was calculated using the Chi-square test for trend.
All statistical tests were two-sided and the level of significance was set at P=0.05. The
95%CI for rates and proportions were calculated using Fisher type exact confidence limits
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with Episheet (Version June 11, 2008, Ken Rothman). All other analyses were conducted
using SPSS 15.0 (SPSS, Inc., Chicago, Illinois).
Results
Socio-demographic Characteristics
Of the total 1997 participants in the baseline study, 1911 were diagnosed with CIN1 or less
and 86 were diagnosed with CIN2+. A total of 59 women were ineligible for follow-up due
to incomplete baseline testing data, and an additional 107 were lost to follow-up. To
evaluate the six-year outcomes of untreated cervical status, we excluded all women had any
cervical therapy at baseline or during the past six years (n=120), women with incomplete
data (n=44) or inconclusive diagnosis (n=58), and deaths from non-cervical causes (n=19)
(Figure 1). Finally, a total of 1590 (80%) women were eligible for data analysis, including
1461 baseline normal women, 99 women with baseline CIN1, and 30 women with CIN2/
CIN3 who refused therapy during the past six years.
Most of the socio-demographic information were comparable between women who were
included in the final analysis (n=1590) and those excluded (n=407) (P>0.05; data not
shown). However, excluded women (n=407) had a higher rate of smoking and HPV
infection, and a higher proportion of cytological abnormalities (P<0.001).
Among women included in the analysis, the mean age, age of menarche and age of sexual
debut for all the participants was 39 years, 16 years, and 20 years, respectively (Table 1).
Age of sexual debut differed marginally between HPV viral load subgroups (P=0.04). All
women were married, and 39.7% of HPV-negative women reported two or more lifetime
sexual partners compared to 52.5% among HPV-positive women (P=0.002). HPV negative
women had less extramarital sex than HPV positive women (P<0.001). Most of the women
were premenopausal, non-smokers and non-drinkers. All other baseline characteristics did
not differ significantly by category of viral load (P>0.05).
Validity of the Screening Test
Using moderate-to-high HPV viral load as the cut-point for colposcopy referral meant
raising the RLU/PC cutoff from 1.0 to 10.0. Although the sensitivity for CIN2+ was reduced
by 12% (97.6% vs. 85.7%), the specificity rose from 84.8% to 90.4%. Moreover, without
loss of negative predictive value (NPV) (99.9% vs. 99.3%), the positive predictive value
(PPV) also rose from 22.5% to 28.9%. The likelihood ratio (LR) was also improved, with
the positive LR rising from 6.4 to 8.9, and negative LR reduced from 0.028 to 0.016.
Furthermore, the referral rate was reduced from 18.1% to 12.9%.
Regression and Progression of Cervical Lesions
Baseline Normal or CIN1—Among the 1560 women with CIN1 or normal status at
baseline, 19 incident cases of CIN2+ were recorded. This includes 13 cases detected through
follow-up and six cases (one CIN2, three CIN3, and two invasive cervical cancers)
confirmed by post-operation histological diagnosis between enrollment and follow-up.
Women who were HPV-negative at baseline had a six-year CIN2+ cumulative incidence of
0.1% (Table 2). However, CIN2+ cumulative incidence increased to 7.9% for women who
were HPV-positive baseline. We observed a dose response relationship, with cumulative
incidence of CIN2+ lesions increasing in proportion to HPV viral load at baseline (negative:
0.1%, low: 1.3%, moderate: 11.1%, and high: 11.7%) (P-trend<0.001). The aHR also
increased in association with viral load (P<0.001) (negative: 1, low: 10.0 (95%CI: 0.9–
110.7), moderate: 75.1 (95%CI: 15.5–364.2) and high: 83.5 (95%CI: 18.0–387.5)). In
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general, women with CIN1 had a higher progressive rate than normal women (8.1% vs.
0.8%).
Women with moderate or high viral load at baseline, but with negative or low viral load at
follow-up, experienced a cumulative incidence 3.0% (95%CI: 0.6–8.8), with a 19-fold
increased risk for CIN2+ compared to those negative at both visits (aHR=19.1, 95%CI: 3.2–
114.5) (Table 3). Women with negative or low viral load at baseline, but having moderate or
high viral load at follow-up, experienced a lower cumulative incidence 1.0% (95%CI: 0.03–
5.7). However, women with moderate or high viral load at both time points experienced a
29.0% (95%CI: 14.5–51.8) cumulative incidence of CIN2+ and an aHR of 188.8 (95%CI:
41.2–864.1).
Baseline CIN2+—In a sub-analysis of the women with CIN2 at baseline (n=25), the
percentage of women who regressed to normal, regressed to CIN1, remained CIN2, and
progressed to CIN3 was 56.0% (14/25), 24.0% (6/25), 4.0% (1/25), and 16.0% (4/25),
respectively. None progressed to cancer. Among women with CIN2 and repeat moderate or
high HPV viral load (n=9), one woman remained CIN2, four regressed to CIN1, and four
progressed to CIN3. Among those with repeat high viral load, the progressive rate of CIN3
increased to 80.0% (4/5). Among the five women with baseline CIN3, two regressed and
three remained as CIN3. None progressed to cancer.
Discussion
Over the course of six years, the cumulative incidence of CIN2+ and the hazard ratio for
CIN2+, among women with CIN1 or less at baseline, increased with increasing HPV viral
load. Compared to women with repeat negative HPV test results, women with repeat
moderate to high HPV viral loads had nearly a 190-fold increased risk for CIN2+. Over the
same time period, 56% of women with CIN2 regressed to normal, 24% regressed to CIN1,
4% remained CIN2, and 16% progressed to CIN3.
Though persistent HPV infection is considered a necessary risk factor for CIN2+ lesion
development, the use of HPV viral load as a short-term predictor for progression to cervical
precancerous lesions has been controversial.11 Some studies have reported that a single
measurement of HPV copy number does not reliably predict the risk of developing cervical
neoplasia.12–14 However, others report that HPV viral load is a potentially valuable clinical
predictor for development of CIN2+ lesions.15,16 Differences may be due to HPV testing
methods; negative studies have tended to use real-time PCR as opposed HC2. However
since HC2 is used in clinical settings worldwide, predictive implications based on the HC2
viral load surrogate (RLU/PC) are more relevant to clinical practice.
Shi’s 2009 analysis of this dataset called attention to the importance of repeat positive HPV
results as a predictor of cervical precancerous lesion development.9 However, the role of
HPV viral load in the development of these lesions was not considered. Our viral load
results cast light on this issue. Based on our data, among women with repeat positive HPV
results, the true high-risk individuals are those with moderate to high viral load, especially
those with repeat moderate to high viral load. Due to the small number of cases, we reported
a relatively large loss in sensitivity for detecting CIN2+ compared with prior studies.17
However, we also provided evidence that, for a single HPV test, using moderate to high
viral load (>10.0 RLU/PC) as the triage cut-off greatly improved the PPV and specificity,
and reduced the referral rate for colposcopy.
A comparable long-term Swedish study reported 54% of CIN2 regressing to normal, 16%
having persistent dysplasia, and 30% progressing to CIN3+.18 Though the proportion
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regressing to normal was nearly identical to that in our study (54% vs. 56%), we found a
substantially smaller percentage of progression to CIN3+ (16% vs. 30%). Our results also
differed from another long-term Nordic study, which reported 53% regression, 24%
persistence, and 21% progression among women with baseline CIN2.19 More recent studies
reported 28% of CIN 2/3 lesions regressing to CIN1 or less over 15 weeks and 68% of CIN2
lesions regressing completely (negative cytology and biopsy) by three years.5,20 There are
multiple possible reasons for these different rates. First, due to our limited sample, our
estimates may be subject to significant random variation. Second, there are almost certainly
important differences between the Western women and Chinese women including, but not
limited to, genetics, nutritional status, age, and HPV type distribution of participants. Third,
length of follow-up was not consistent and limits comparability. Finally, with regard to
pathology, poor reliability in CIN2 diagnosis may also contribute to the discrepancies
between studies. 21
Given the high probability of transient HPV infection and over-diagnosis of CIN2, which
may spontaneously regress among women younger than 35 years, HPV-based screening has
not been recommended as a primary screening method below a certain age.22 Furthermore,
given that half of women with CIN2 regressed to normal over the course of six years, new
biomarkers are crucial for triage of patients at the clinical threshold of therapy. Previous
studies report that HPV16, HPV18, p16INK4a, Ki67, p53 and high methylation levels of
specific sites in the HPV L1 gene could serve as potential biomarkers for progression to
high-grade CIN lesions and cervical cancer.23,24 However, in the absence of consensus
regarding definitive new predictive biomarkers, our study shows that moderate to high HPV
viral load can act as an alternative predictor for progression of high-grade CIN among
women over age 35 years. Furthermore, as HPV viral load could be read simultaneously
with the HC2 result, this triage method is especially well-suited for areas using HC2 as the
primary screening method and lacking financial support for additional biomarker testing.
Our study was the first Chinese prospective study investigating the natural history of
different CIN lesions associated with varied HPV viral load. A key strength of our study is
the rigorous assessment of each woman’s baseline pathological status. In 1999, no gold
standard screening method for cervical cancer was identified and Xiangyuan County was a
high-risk area with a high mortality of cervical cancer. For the purpose of evaluation of
different screening methods, each woman had her pathological status determined by biopsies
and ECC. A second strength was the ability to study the natural progressive and regressive
rates of CIN2+, which is not readily replicable. Though current clinical guidelines
recommend that women with CIN2+ lesions should be referred for immediate therapy,3 our
study was conducted in a rural county in 1999 where such therapy was provided on a
voluntary basis and were not readily acceptable for women without visible lesions or
obvious pain. Third, the pathological slides of the baseline and follow-up study were read by
the same pathological panel, which made the results more comparable and reliable.
Our study also has significant limitations. First, our conclusions are directly applicable to
women 35–45 years old living in a high incidence areas and do not speak to the situation of
younger women.Second, although a positive trend was found between the aHR for CIN2+
and HPV viral load subgroups, the confidence intervals overlapped among different HPV
viral load subgroups due to the small sample size of endpoints. Third, women who refused
treatment at baseline may have had smaller lesions than those who received therapy, thus we
may have overestimated the regression rate. We also used CIN2 other than the more reliable
CIN3 diagnosis as the study endpoint due to the small number of cases.25 Additionally,
since we only tested women at the beginning and end of the six-year period, we were unable
to capture incident CIN2+ lesions that spontaneously regressed between visits. Similarly, we
were unable to determine if women with repeat positive HPV test results had persistent
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infection or were re-infected subsequent to clearing the infection. Finally, we lacked
genotyping data which have allowed us to examine HPV type specific differences in rates of
progression and regression.
In conclusion, based on our data, women with a negative baseline HPV test could be
protected for at least six years.9 In contrast, women with moderate to high viral load,
especially those with repeat high viral load, had extremely high risk for developing CIN2+
lesions. To reduce CIN2 overtreatment, novel biomarkers are needed for triage. Locales
using HC2 HPV testing as the primary screening method, and lacking high-quality cytology-
based screening systems, should consider viral load as an alternative method to triage
women over age 35 years for colposcopy. Viral load may also serve as a predictor for CIN2
progression until additional biomarkers become available. Long-term studies with larger
sample sizes and broader age distributions are needed to validate our findings.
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Abbreviations
aHR age-adjusted hazard ratios
ASC-H atypical squamous cells: cannot exclude HSIL
ASCUS atypical squamous cells of undetermined significance
CI confidence intervals
CICAMS Cancer Institute, Chinese Academy of Medical Sciences
CIN cervical intraepithelial neoplasia
CIN2+ CIN grade 2 or worse
CIN3+ CIN grade 3 or worse
ECC endocervical curettage
HC2 Hybrid Capture 2
HPV human papillomavirus
HSIL high-grade squamous intraepithelial lesions
LSIL low-grade squamous intraepithelial lesions
RLU/PC the ratio of relative light units to standard positive control
SCJ squamocolumnar junction
VIA visual inspection with acetic acid
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Table 3
Cumulative incidence and risk of cervical intraepithelial neoplasia grade 2 or worse (CIN2+) in association
with varied HPV viral load among normal women or women with CIN1 at baseline, stratified by combinations
of HPV viral load at baseline and follow-up.
HPV Viral Load No. CIN2+/No. women Cumulative Incidence of CIN2+ aHR‡ 95% CI
Repeat Negative 2/1199 0.2% 1 -
Single/ Repeat Low load† 0/124 - - -
Single Moderate/ High load at baseline 3/100 3.0% 19.1 3.2–114.5
Single Moderate/ High load at follow up 1/97 1.0% 6.8 0.6–74.8
Repeat Moderate/ High load† 11/38 29.0% 188.8 41.2–864.1
†
 Viral load categories represent the maximum measured viral load for a given woman for either time point.
‡
 aHR=Hazard Ratio adjusted for age, number of full-term births and number of lifetime sexual partners.
Int J Gynecol Cancer. Author manuscript; available in PMC 2014 May 01.
